Show simple item record

dc.contributor.authorSzabo, Gyongyi
dc.contributor.authorGavala, C.
dc.contributor.authorMandrekar, Pranoti
dc.date2022-08-11T08:08:37.000
dc.date.accessioned2022-08-23T16:01:22Z
dc.date.available2022-08-23T16:01:22Z
dc.date.issued2001-08-29
dc.date.submitted2010-04-21
dc.identifier.citationJ Investig Med. 2001 Sep;49(5):442-9.
dc.identifier.issn1081-5589 (Linking)
dc.identifier.pmid11523700
dc.identifier.urihttp://hdl.handle.net/20.500.14038/31105
dc.description.abstractMyeloid dendritic cells (DCs) are pivotal in the recognition of alloantigens and, therefore, in the induction of allograft rejection. Induction of alloreactive T cell proliferation by myeloid DCs depends on the maturation of DCs, the expression of costimulatory molecules, and the cytokine environment. This study investigated the effects of tacrolimus and cyclosporine A (CsA) on DC maturation and allostimulatory capacity. Myeloid DCs were propagated from normal blood monocytes with interleukin (IL) 4 and GM-CSF for 7 days in the presence or absence of tacrolimus (FK506; 10 nM) or CsA (1 microg/mL). Exposure of DCs during maturation to tacrolimus or CsA resulted in no significant change in the expression of DC phenotypic markers, including CD80, CD86, and HLA Class I and II antigens determined by flow cytometry. T cell proliferation in one-way, mixed-leukocyte reaction experiments revealed a decreased allostimulatory capacity of DCs that matured in the presence of tacrolimus or CsA compared with untreated controls (P<0.02). Production of inflammatory cytokines, tumor necrosis factor alpha (P<0.04) and IL-12 (P<0.04) in response to lipopolysaccharide (1 microg/mL) or staphylococcal enterotoxin B (1 microg/mL) induction was significantly reduced in DCs exposed to tacrolimus or CsA during maturation. In contrast, production of the immuninhibitory cytokine IL-10 was not decreased in tacrolimus- or CsA-treated DCs. These results suggest that tacrolimus and CsA inhibit the allostimulatory capacity of in vitro-generated myeloid DCs without significant effects on DC phenotypic maturation. Decreased production of IL-12 and tumor necrosis factor alpha, but not of IL-10, is likely to contribute to the impaired accessory-cell function of tacrolimus- and CsA-treated DCs. Thus, tacrolimus and CsA can inhibit recognition of alloantigens by decreasing the accessory-cell capacity of monocyte-derived myeloid DCs.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=11523700&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.2310/6650.2001.33789
dc.subjectCyclosporine
dc.subjectCytokines
dc.subjectDendritic Cells
dc.subjectHumans
dc.subjectImmunosuppressive Agents
dc.subjectIsoantigens
dc.subject*Lymphocyte Activation
dc.subjectMonocytes
dc.subjectT-Lymphocytes
dc.subjectTacrolimus
dc.subjectGastroenterology
dc.subjectImmunology and Infectious Disease
dc.titleTacrolimus and cyclosporine A inhibit allostimulatory capacity and cytokine production of human myeloid dendritic cells
dc.typeJournal Article
dc.source.journaltitleJournal of investigative medicine : the official publication of the American Federation for Clinical Research
dc.source.volume49
dc.source.issue5
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/gastroenterology_pp/31
dc.identifier.contextkey1282326
html.description.abstract<p>Myeloid dendritic cells (DCs) are pivotal in the recognition of alloantigens and, therefore, in the induction of allograft rejection. Induction of alloreactive T cell proliferation by myeloid DCs depends on the maturation of DCs, the expression of costimulatory molecules, and the cytokine environment. This study investigated the effects of tacrolimus and cyclosporine A (CsA) on DC maturation and allostimulatory capacity. Myeloid DCs were propagated from normal blood monocytes with interleukin (IL) 4 and GM-CSF for 7 days in the presence or absence of tacrolimus (FK506; 10 nM) or CsA (1 microg/mL). Exposure of DCs during maturation to tacrolimus or CsA resulted in no significant change in the expression of DC phenotypic markers, including CD80, CD86, and HLA Class I and II antigens determined by flow cytometry. T cell proliferation in one-way, mixed-leukocyte reaction experiments revealed a decreased allostimulatory capacity of DCs that matured in the presence of tacrolimus or CsA compared with untreated controls (P<0.02). Production of inflammatory cytokines, tumor necrosis factor alpha (P<0.04) and IL-12 (P<0.04) in response to lipopolysaccharide (1 microg/mL) or staphylococcal enterotoxin B (1 microg/mL) induction was significantly reduced in DCs exposed to tacrolimus or CsA during maturation. In contrast, production of the immuninhibitory cytokine IL-10 was not decreased in tacrolimus- or CsA-treated DCs. These results suggest that tacrolimus and CsA inhibit the allostimulatory capacity of in vitro-generated myeloid DCs without significant effects on DC phenotypic maturation. Decreased production of IL-12 and tumor necrosis factor alpha, but not of IL-10, is likely to contribute to the impaired accessory-cell function of tacrolimus- and CsA-treated DCs. Thus, tacrolimus and CsA can inhibit recognition of alloantigens by decreasing the accessory-cell capacity of monocyte-derived myeloid DCs.</p>
dc.identifier.submissionpathgastroenterology_pp/31
dc.contributor.departmentDepartment of Medicine, Rheumatology Division
dc.contributor.departmentDepartment of Medicine, Division of Gastroenterology
dc.source.pages442-9


This item appears in the following Collection(s)

Show simple item record